---
layout: default
title: Venetoclax
parent: Model Prediction Only (L5)
nav_order: 1286
evidence_level: L5
indication_count: 10
---

# Venetoclax
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Venetoclax: From Chronic Lymphocytic Leukemia to CLL/SLL with Immunoglobulin Heavy Chain Variable-Region Somatic Hypermutation

## One-Sentence Summary

Venetoclax is an oral BCL-2 inhibitor marketed in the United States as Venclexta (AbbVie). The label indication text is not in the data provided, but the literature in the Evidence Pack describes it as approved for chronic lymphocytic leukemia (CLL).
The TxGNN model predicts it may be effective for **CLL/SLL with immunoglobulin heavy chain variable-region (IGHV) somatic hypermutation**, a subtype of the approved parent disease.
Currently **0 clinical trials** and **0 publications** are linked to this specific subtype, so the only support is the model score.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not provided in the label data (CLL per literature in the pack) |
| Predicted New Indication | CLL/SLL with immunoglobulin heavy chain variable-region gene somatic hypermutation |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 3 records (all NDA208573, i.e. one distinct NDA) |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known information, venetoclax is a selective BCL-2 inhibitor. Its efficacy in CLL is described in the pack's literature (PMID 28724540), and mechanistically it may be applicable to this CLL/SLL subtype.

CLL/SLL cells depend on BCL-2 for survival, so blocking BCL-2 is biologically plausible. The predicted disease is the IGHV-mutated subtype of the parent CLL/SLL entity. The IGHV-mutated (post-germinal center) form is generally regarded as the better-prognosis subgroup.

This prediction is probably driven by the node's closeness to the parent CLL/SLL disease in the knowledge graph, not by subtype-specific evidence. The pack has no trial or publication tied to this subtype, so the mechanistic argument is inherited from the parent disease and has not been tested for the subtype itself.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

The three license records in the data are identical, so they are shown once.

| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---------|------|------|-----------|
| NDA208573 | Venclexta | Tablet, film coated (oral) | AbbVie Inc. |

The approved indication text was not provided in the data.

---

## Cytotoxicity

Venetoclax is an antineoplastic agent used in hematologic malignancies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (BCL-2 inhibitor, induces mitochondrial apoptosis) |
| Myelosuppression Risk | Not quantified in the pack. Literature in the pack (PMID 35659041) notes myelosuppression, together with tumor lysis syndrome, as the most commonly encountered toxicity in lymphoid malignancies |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | CBC with differential; renal function and serum chemistry/electrolytes for tumor lysis risk |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information. The FDA package insert warnings and contraindications were not available in the data, and no drug interaction records were found.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The only support for this subtype is a TxGNN score of 99.55%. There are no linked trials or publications, and the safety section is empty because the package insert was not retrieved. The mechanistic argument rests entirely on the parent CLL/SLL disease.

Other predictions in the same pack have much stronger evidence. Acute myeloid leukemia (L2, Proceed with Guardrails), CML and follicular lymphoma (both L2, Research Question) have many Phase 1/2 venetoclax trials. These are better candidates to prioritize.

**To proceed, the following is needed:**
- FDA package insert (warnings, contraindications, indication text), which currently blocks safety screening
- Detailed mechanism of action data from DrugBank
- Subtype-specific evidence, such as IGHV-mutated subgroup results from existing venetoclax CLL trials (e.g. the MURANO final analysis, PMID 40009494, and the Phase 3 CLL13 trial, NCT02950051, both listed under other predictions in the pack)
- A reviewer's judgment on whether the parent CLL/SLL evidence can be credited to this subtype
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

